Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti‐aromatase activity assay examining exemestane and its derivatives

Exemestane (EXE) treats estrogen receptor positive (ER+) breast cancer in postmenopausal women by inhibiting the estrogen‐synthesizing cytochrome P450 CYP19A1. Variability in the severity and incidence of side effects as well as overall drug efficacy may be partially explained by genetic factors, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Peterson, Amity, Xia, Zuping, Chen, Gang, Lazarus, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464342/
https://www.ncbi.nlm.nih.gov/pubmed/28603632
http://dx.doi.org/10.1002/prp2.313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464342/
https://www.ncbi.nlm.nih.gov/pubmed/28603632
http://dx.doi.org/10.1002/prp2.313

Ejemplares similares